Dr. Gary Loveman Joins Seraph’s Board

DETROIT, Feb. 19, 2019 – Seraph Biosciences, Inc., creator of Seraspec®, is pleased to announced that Dr. Gary Loveman, former executive vice president of Aetna, Inc., and former CEO of Caesars Entertainment Corp., has joined Seraph’s board of directors.

Dr. Loveman currently serves on the board of trustees at Boston Children’s Hospital and is a Senior Lecturer in the Department of Finance at Harvard Business School. During his tenure at Aetna, Inc., Dr. Loveman led the company’s Consumer Health and Service business, where he collaborated with healthcare providers to improve the cost and quality of care for Aetna members. Prior to joining Aetna, Dr. Loveman was chairman of the Business Roundtable’s Health & Retirement Committee, an organization devoted to improving the quality and cost of medical care and retirement plans across the nation.

“Seraph’s technology provides the potential for convenient, low-cost, diagnosis and therapy for a wide range of healthcare consumers,” said Loveman. “In my view, it represents a transformation of healthcare delivery at the local level. I’m very excited to be a part of Seraph’s efforts to finalize the technology and bring it to market.”

Over the course of his 17-year tenure as chairman, CEO, and president of Caesars Entertainment, Dr. Loveman championed health and wellness programs for the company’s 70,000 employees. He is known as a pioneer in the use of advanced data analytics to reward loyalty and improve customer service. Dr. Loveman was voted “Best CEO in the Hospitality Industry” four times by Institutional Investor magazine.

Dr. Loveman was introduced to the technology by fellow Seraph board member Matt Cullen, CEO of JACK Entertainment LLC and principal at Rock Ventures LLC. Loveman and Cullen developed a strong professional relationship through their work in the hospitality and gaming industries.

“When Gary moved from Caesars to Aetna, I was intrigued by his focus on the healthcare industry, wellness and health,” Cullen explained. “Seraph is at a point in its evolution where it is determining how to best use its revolutionary product and identify its core audience. Gary’s experience at Aetna has given him deep knowledge of the factors Seraph is trying to understand.”

About Seraph Biosciences, Inc.

Incorporated in 2016, Seraph Biosciences, Inc. is a biotechnology company dedicated to commercializing Seraspec® – a fully automated pathogen identification platform capable of delivering near real-time pathogen detection. Based in Detroit, Michigan, Seraph’s mission is to provide disruptive biomedical solutions to front-line providers and their patients at the point of care.